Editas Medicine (EDIT) has commenced an underwritten public offering of common stock and pre-funded warrants, along with accompanying warrants to purchase additional shares, the gene editing company said Tuesday.
The company said it has not yet determined the actual size or terms of the offering.
The company's shares were down 18% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments